Last reviewed · How we verify
doxorubicin-eluting beads
Doxorubicin-eluting beads deliver the chemotherapy drug doxorubicin directly to tumors via transcatheter arterial chemoembolization, combining local drug delivery with ischemic tumor necrosis.
Doxorubicin-eluting beads deliver the chemotherapy drug doxorubicin directly to tumors via transcatheter arterial chemoembolization, combining local drug delivery with ischemic tumor necrosis. Used for Hepatocellular carcinoma, Liver metastases.
At a glance
| Generic name | doxorubicin-eluting beads |
|---|---|
| Also known as | Adriamycin, Lipidol-Doxorubicin emulsion |
| Sponsor | Swiss Cancer Institute |
| Drug class | Chemotherapy-eluting embolic beads |
| Target | Topoisomerase II (via doxorubicin payload) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
These beads are loaded with doxorubicin and injected into the arterial blood supply feeding a tumor, where they lodge in tumor vasculature. This approach delivers high local concentrations of doxorubicin while simultaneously occluding blood flow to starve the tumor of oxygen and nutrients. The dual mechanism of chemotherapy and embolization maximizes tumor kill while minimizing systemic exposure.
Approved indications
- Hepatocellular carcinoma
- Liver metastases
Common side effects
- Abdominal pain
- Nausea and vomiting
- Fatigue
- Elevated liver enzymes
- Post-embolization syndrome
Key clinical trials
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (PHASE2)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma (PHASE2, PHASE3)
- DEB-TACE vs cTACE in HCC After TIPS (PHASE3)
- Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment (PHASE2)
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (PHASE2)
- Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant (PHASE3)
- Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |